Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Rang in aandelen #33300
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Aandeelprijs
$0.4264
Laatst gesynchroniseerd: 2022-09-14
Marktkapitalisatie
$7.93M
Verandering (1 dag)
-16.44%
Verandering (1 jaar)
0.00%
Land
US
Handel Caladrius Biosciences, Inc. (CLBS)

Categorie

Koersgeschiedenis voor Caladrius Biosciences, Inc. (CLBS)
Hoogste slotkoers: $0.50 op 2022-09-01

Laagste slotkoers: $20.36 op 2015-06-01
Koersgeschiedenis van Caladrius Biosciences, Inc. van 2015 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2022 -43.51%
2021 -42.36%
2020 -36.52%
2019 -44.38%
2018 26.20%
2017 2.72%
2016 -70.04%
2015 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$511.97 30.34%
US
$984.83 50.62%
NL
$736.38 7.15%
CH
$1.07K -6.40%
KR
$255.62 13.43%
BE